

Raltegravir 800 mg Once Daily versus 400 mg Twice Daily
QDMRK Trial

[Raltegravir 800 mg Once Daily or 400 mg Twice Daily] + TDF-FTC QDMRK: Study Design

Study Design: QDMRK Study


- **Background:** Randomized, double-blind, phase 3 trial in antiretroviral-naïve persons with HIV to compare the efficacy of once-daily with twice-daily Raltegravir.
- **Inclusion Criteria (n = 775)**
 - Age ≥18 years
 - Antiretroviral-naïve
 - HIV RNA >5,000 copies/mL
 - No CD4 criteria
 - No relevant mutations
- **Treatment Arms**
 - Raltegravir 800 mg QD + TDF-FTC
 - Raltegravir 400 mg BID + TDF-FTC

**Raltegravir 800 mg QD +
TDF-FTC**
(n = 386)

**Raltegravir 400 mg BID +
TDF-FTC**
(n = 389)

[Raltegravir 800 mg Once Daily or 400 mg Twice Daily] + TDF-FTC QDMRK: Results

Virologic Response: Week 48 (non-completer = failure)



[Raltegravir 800 mg Once Daily or 400 mg Twice Daily] + TDF-FTC QDMRK: Conclusions

Interpretation: “Despite high response rates with both regimens, once-daily raltegravir cannot be recommended in place of twice-daily dosing.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

